149 related articles for article (PubMed ID: 25513719)
1. Computational design and discovery of nanomolar inhibitors of IκB kinase β.
Park H; Shin Y; Choe H; Hong S
J Am Chem Soc; 2015 Jan; 137(1):337-48. PubMed ID: 25513719
[TBL] [Abstract][Full Text] [Related]
2. Discovery of picomolar ABL kinase inhibitors equipotent for wild type and T315I mutant via structure-based de novo design.
Park H; Hong S; Kim J; Hong S
J Am Chem Soc; 2013 Jun; 135(22):8227-37. PubMed ID: 23679864
[TBL] [Abstract][Full Text] [Related]
3. Novel IKKβ inhibitors discovery based on the co-crystal structure by using binding-conformation-based and ligand-based method.
Huang JJ; Wu XW; Jia JM; Guo XK; Xue X; Jiang ZY; Zhang SL; Zhang XJ; Sun HP; You QD
Eur J Med Chem; 2013 May; 63():269-78. PubMed ID: 23501112
[TBL] [Abstract][Full Text] [Related]
4. Systematic Computational Design and Identification of Low Picomolar Inhibitors of Aurora Kinase A.
Park H; Jung HY; Mah S; Hong S
J Chem Inf Model; 2018 Mar; 58(3):700-709. PubMed ID: 29401391
[TBL] [Abstract][Full Text] [Related]
5. Combination of pharmacophore model development and binding mode analyses: identification of ligand features essential for IκB kinase-beta (IKKβ) inhibitors and virtual screening based on it.
Sun HP; Zhu J; Chen FH; Zhang SL; Zhang Y; You QD
Eur J Med Chem; 2011 Sep; 46(9):3942-52. PubMed ID: 21708416
[TBL] [Abstract][Full Text] [Related]
6. Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 2: improvement of potency in vitro and in vivo.
Shimizu H; Yasumatsu I; Hamada T; Yoneda Y; Yamasaki T; Tanaka S; Toki T; Yokoyama M; Morishita K; Iimura S
Bioorg Med Chem Lett; 2011 Feb; 21(3):904-8. PubMed ID: 21232950
[TBL] [Abstract][Full Text] [Related]
7. Small molecule inhibitors of IκB kinase β: A chip-based screening and molecular docking simulation.
Cho YW; Lim HJ; Han MH; Kim BC; Han S
Bioorg Med Chem; 2020 May; 28(9):115440. PubMed ID: 32205046
[TBL] [Abstract][Full Text] [Related]
8. IKKbeta inhibitors identification part I: homology model assisted structure based virtual screening.
Nagarajan S; Doddareddy Mr; Choo H; Cho YS; Oh KS; Lee BH; Pae AN
Bioorg Med Chem; 2009 Apr; 17(7):2759-66. PubMed ID: 19285872
[TBL] [Abstract][Full Text] [Related]
9. Consensus scoring approach to identify the inhibitors of AMP-activated protein kinase α2 with virtual screening.
Park H; Eom JW; Kim YH
J Chem Inf Model; 2014 Jul; 54(7):2139-46. PubMed ID: 24915156
[TBL] [Abstract][Full Text] [Related]
10. Structure-Based Virtual Screening and De Novo Design to Identify Submicromolar Inhibitors of G2019S Mutant of Leucine-Rich Repeat Kinase 2.
Park H; Kim T; Kim K; Jang A; Hong S
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361616
[TBL] [Abstract][Full Text] [Related]
11. Theoretical study on the interaction of pyrrolopyrimidine derivatives as LIMK2 inhibitors: insight into structure-based inhibitor design.
Shen M; Zhou S; Li Y; Li D; Hou T
Mol Biosyst; 2013 Oct; 9(10):2435-46. PubMed ID: 23881296
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of novel
Xie X; Tu J; You H; Hu B
Drug Des Devel Ther; 2017; 11():1439-1451. PubMed ID: 28553074
[TBL] [Abstract][Full Text] [Related]
13. Discovery of thienopyrimidine-based FLT3 inhibitors from the structural modification of known IKKβ inhibitors.
Park CH; Lee C; Yang JS; Joe BY; Chun K; Kim H; Kim HY; Kang JS; Lee JI; Kim MH; Han G
Bioorg Med Chem Lett; 2014 Jun; 24(12):2655-60. PubMed ID: 24813730
[TBL] [Abstract][Full Text] [Related]
14. Discovery of imidazo[1,2-b]pyridazine derivatives as IKKbeta inhibitors. Part 1: Hit-to-lead study and structure-activity relationship.
Shimizu H; Tanaka S; Toki T; Yasumatsu I; Akimoto T; Morishita K; Yamasaki T; Yasukochi T; Iimura S
Bioorg Med Chem Lett; 2010 Sep; 20(17):5113-8. PubMed ID: 20675134
[TBL] [Abstract][Full Text] [Related]
15. Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.
Berger DM; Torres N; Dutia M; Powell D; Ciszewski G; Gopalsamy A; Levin JI; Kim KH; Xu W; Wilhelm J; Hu Y; Collins K; Feldberg L; Kim S; Frommer E; Wojciechowicz D; Mallon R
Bioorg Med Chem Lett; 2009 Dec; 19(23):6519-23. PubMed ID: 19864136
[TBL] [Abstract][Full Text] [Related]
16. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, initial SAR and biological evaluation of 1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine derived inhibitors of IkappaB kinase.
Kempson J; Guo J; Das J; Moquin RV; Spergel SH; Watterson SH; Langevine CM; Dyckman AJ; Pattoli M; Burke JR; Yang X; Gillooly KM; McIntyre KW; Chen L; Dodd JH; McKinnon M; Barrish JC; Pitts WJ
Bioorg Med Chem Lett; 2009 May; 19(10):2646-9. PubMed ID: 19376699
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of N-phenylthieno[2,3-d]pyrimidin-4-amines as inhibitors of FGFR1.
Gryshchenko AA; Bdzhola VG; Balanda AO; Briukhovetska NV; Kotey IM; Golub AG; Ruban TP; Lukash LL; Yarmoluk SM
Bioorg Med Chem; 2015 May; 23(9):2287-93. PubMed ID: 25817240
[TBL] [Abstract][Full Text] [Related]
19. The discovery of thienopyridine analogues as potent IkappaB kinase beta inhibitors. Part II.
Wu JP; Fleck R; Brickwood J; Capolino A; Catron K; Chen Z; Cywin C; Emeigh J; Foerst M; Ginn J; Hrapchak M; Hickey E; Hao MH; Kashem M; Li J; Liu W; Morwick T; Nelson R; Marshall D; Martin L; Nemoto P; Potocki I; Liuzzi M; Peet GW; Scouten E; Stefany D; Turner M; Weldon S; Zimmitti C; Spero D; Kelly TA
Bioorg Med Chem Lett; 2009 Oct; 19(19):5547-51. PubMed ID: 19716697
[TBL] [Abstract][Full Text] [Related]
20. Small molecule binding to inhibitor of nuclear factor kappa-B kinase subunit beta in an ATP non-competitive manner.
Napoleon JV; Singh S; Rana S; Bendjennat M; Kumar V; Kizhake S; Palermo NY; Ouellette MM; Huxford T; Natarajan A
Chem Commun (Camb); 2021 May; 57(38):4678-4681. PubMed ID: 33977973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
